versus

Sanuwave Announces Q3 FY2025 Financial Results

Q3 2025 revenues were $11.5 million, up 22% from $9.4 million in Q3 2024. This represents the highest quarterly revenues in…

3 weeks ago

Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference

October 24, 2025 07:00 ET  | Source: Sagimet Biosciences Inc. Denifanstat met all primary and secondary endpoints versus placebo and…

1 month ago

PSMAddition data show Novartis Pluvicto delays progression to end-stage prostate cancer

Basel, October 19, 2025 – Novartis today presents new Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan) data from the Phase III PSMAddition…

1 month ago

Novo Nordisks oral semaglutide 25 mg (Wegovy in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study

Oral semaglutide 25 mg (the once-daily pill formulation of Wegovy®) achieved significant weight loss, with one in three study participants…

2 months ago

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine

Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed mean weight reduction in the highest range of…

5 months ago

Embracing Powertrain Diversity, GWM Continues to Enhance Clean Diesel Capabilities for Off-Roading

BAODING, China--(BUSINESS WIRE)--While new energy vehicles continue to gain momentum worldwide, efficient diesel power remains a compelling choice—especially in challenging…

5 months ago